This book offers valuable insights into the latest concepts and findings from epidemiologic, clinical and basic studies in the burgeoning area of early-life environmental exposure and diseases. The book is divided into five parts, starting with an overview of environmental exposure measurement and evaluation, followed by a review of the effects of exposure to various substances like tobacco smoke, pesticides and metals as well as stress on offspring's health. It then discusses the developmental origins of a range of childhood diseases that affect growth, neural development and the immune system, and highlights the importance of longitudinal studies that measure exposure at potentially sensitive time points during childhood. It also provides up-to-date evidence of the intergenerational/transgenerational effects of early-life environmental exposure, especially via genetic and epigenetic pathways. Allowing readers to gain a thorough understanding of the predominating aspects of early-life environmental exposure and diseases, the book also provides a basis for developing environmental and health policies that could have wide and long-term impacts on human health.

"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

*Presents the latest research in the field of drug discovery *Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

All books on the market which have been written on the subject of botulinum toxin therapy focus on treatment of hyperactive movement disorders, autonomic dysfunction (bladder, sweat and salivary glands) and some pain indications (migraine). Reference to pre-or post -surgical indications are brief and often out-dated. No book has information on dentistry or veterinary medicine. This book provides up-to-date information on botulinum toxin therapy in surgical fields. It is also the only book in the market that provides information on botulinum toxin therapy in dentistry and veterinary medicine, furnishing the latest information. Botulinum Toxin Treatment in Surgery, Dentistry, and Veterinary Medicine appeals to many disciplines including surgery, dentistry and veterinary medicines well as appealing to neurologists and internists.

"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

*Presents the latest research in the field of drug discovery *Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

This volume provides readers with the most updated scientific information on the efficacy and safety of medicines for children and adolescents. The book enriches the understanding of pediatric pharmacotherapy for health professionals, regulatory agencies, pharmaceutical companies and learned societies. It contains important information on the pharmacodynamics and pharmacokinetics of drugs. It summarizes the latest investigations on the effects of pharmacological treatments in relation to and dependent on age, gender, fat mass and disease status. Therefore and importantly, this volume reviews the latest data on how pharmacotherapy has to be adjusted and personalized in regards to stages of development and during the pediatric lifespan from neonate through adolescence. In addition, the topic of rare diseases and special challenges for pharmacotherapy will be included and will provide readers with the necessary knowledge to handle complex diseases and treatment strategies especially in relation to pharmacotherapy of rare and orphan diseases.

This volume discusses how environmental pollutants are involved in the pathogenesis of neurological disorders, and covers specific mechanisms and risk factors, as well as the necessary strategies to reduce the adverse impacts of environmental pollutants on the human nervous system. With a collection of contributions from experts in environmental pollution, neurology and pharmaceutical chemistry, the book provides both an introduction to the pathogenesis of neurodegeneration, including the types and different classes of neurological disorders, and studies demonstrating the clear link between environmental contaminants (e.g. pesticides, smoking, mycotoxins, persistent organic pollutants (POP's), polychlorinated biphenyls, phthalates, nanomaterials) and the development of neurological disorders in vulnerable populations. The book fills in a gap in research on the topic by also covering state-of-the-art treatment strategies and mitigation measures for each type of pollutant. The book will be of interest to environmental scientists, pharmacologists, toxicologists, biochemists, biotechnologists, and food and drug regulatory organizations.

Nanobiomaterials in Drug Delivery: Applications of Nanobiomaterials presents novel approaches regarding nanostructured drug delivery systems, revealing the most investigated materials for the development of particular nanobioshuttles. This book brings the results of current research to reach those who wish to use this knowledge in an applied setting, providing one coherent text, with focused chapters and easily accessible information. At its core, it is a collection of titles, bringing together many of the novel applications these materials have in biology, also discussing the advantages and disadvantages of each application and the perspectives of the technologies based on these findings. At the moment, there is no other comparable book series covering all the subjects approached in this set of titles.

This book highlights different natural products that are derived from the plants and microbes that have shown potential as the lead compounds against infectious diseases and cancer. Natural products represent an untapped source of strikingly diverse chemotypes with novel mechanisms of action and the potential to serve as anticancer and anti-infective agents. The book discusses a range of biotechnologically valuable bioactive compounds and secondary metabolites that have been derived from plant and microorganisms from various ecological niches. It also reviews the latest developments in the field of genomics, bioinformatics and industrial fermentation for harnessing the microbial products for commercial applications. In turn, the book's closing section reviews important biotechnological applications of various natural products. Combining the expertise of specialists in this field, the book's goal is to promote the further investigation of natural sources for the development of standardized, safe and effective therapies.

This book exposes the skyrocketing rate of antipsychotic drug prescriptions for children, identifies grave dangers when children's mental health care is driven by market forces, describes effective therapeutic care for children typically prescribed antipsychotics, and explains how to navigate a drug-fueled mental health system. Since 2001, there has been a dramatic increase in the use of antipsychotics to treat children for an ever-expanding list of symptoms. The prescription rate for toddlers, preschoolers, and middle-class children has doubled, while the prescribing rate for low-income children covered by Medicaid has quadrupled. In a majority of cases, these drugs are neither FDA-approved nor justified by research for the children's conditions. This book examines the reasons behind the explosion of antipsychotic drug prescriptions for children, spotlighting the historical and cultural factors as well as the role of the pharmaceutical industry in this trend; and discusses the ethical and legal responsibilities and ramifications for non-MDs-psychologists in particular-who work with children treated with antipsychotics. Contributors explain how the pharmaceutical industry has inserted itself into every step of medical education, rendering objectivity in the scientific understanding, use, and approvals of such drugs impossible. The text describes the relentless marketing behind the drug sales, even going as far as to provide coloring and picture books for children related to the drug at issue. Valuable information about legal recourse that families and therapists can take when their children or patients have been harmed by antipsychotic drugs and alternative approaches to working with children with emotional and behavioral challenges is also provided. A chapter on effective parenting coauthored by a leading parenting expert, Laura Berk Contributions by noted medical journalist Robert Whitaker, author of Anatomy of an Epidemic Information on legal issues by Harvard-educated lawyer Jim Gottstein Insights from former pharmaceutical industry insider, Gwen Olsen An examination of community approaches to children's mental health care by internationally known psychologist Stuart Shanker

A single source for accurate scientific information on herbal remedies! This comprehensive handbook (comprised of two volumes of 700+ pages each) provides a snapshot of 160 herbal products that have been tested in clinical trials. Details of the products and the clinical trials they underwent are here in an easy-to-read, at-a-glance format. Each botanical profile in The Handbook of Clinically Tested Herbal Remedies contains a summary section (table, text and references), followed by product information and clinical trials for that particular product. An evaluation of the strength of the evidence from the trials, along with the context for therapeutics is included to give you a complete picture of each remedy and its usefulness or lack thereof. If there is more than one product based on a particular botanical then the trials are grouped according to the product. This valuable book also makes purchasing easy with manufacturer contact information. With over 30 individual botanicals and 10 multi-ingredient formulas, 160 products and 360 clinical studies, The Handbook of Clinically Tested Herbal Remedies is the book you need to make an informed selection of herbal products. Not only does it list proprietary herbal products that have been tested in controlled clinical studies and provide a rating of the quality of those trials, but, it also describes the fundamentals of herbal medicine, including regulation, characterization, standardization, bioavailability, efficacy, safety, pharmacopoeial monographs as well as incentives, or lack of incentive, for US and European manufacturers to conduct clinical studies. Contributors to the chapters describing the fundamentals of herbal medicine include: * the late Dr. Varro Tyler, Distinguished Professor Emeritus at Purdue University and co-author of Tyler's Honest Herbal, Rational Phytotherapy, and Tyler's Herbs of Choice * Loren Israelsen, JD, president of the LDI group * Tieraona Low Dog, MD, Chair of the USP Dietary Supplement Information Committee * Joerg Grunwald, PhD, co-author of the Physicians Desk Reference (PDR) for Herbal Medicines, and Stefan Spiess, RPh, President of Grunwalder GmbH * Anton Biber, PhD, and Friedrich Lang, PhD, experts in the bioavailability of herbal medicine at Dr. Willmar Schwabe GmbH & Co., Germany * Anthony Almada, MSc, founder and Chief Scientific Officer of IMAGINutrition, Inc. * Joseph M. Betz, PhD, Director of the Dietary Supplements Methods and Reference Materials Program at the NIH Office of Dietary Supplements * Ezra Bejar, PhD, president of Plant Bioassay * Uwe Koetter, PhD, Director of New OTC and Dietary Supplement Product Development at GlaxoSmithKline * Srini Srinivasan, PhD, Vice President of the Dietary Supplement Verification Program of the United States Pharmacopeia (USP) * Roy Upton, Executive Director of the American Herbal Pharmacopoeia. All of the clinical trials in The Handbook of Clinically Tested Herbal Remedies were rated as to their Level of Evidence according to a system designed by Tieraona Low Dog, MD, Chair of the United States Pharmacopoeia Dietary Supplements/Botanicals Expert Panel and a member of the White House Commission on Complementary and Alternative Medicine. The reviewers of the clinical trials included Karriem Ali, MD; Richard Aranda, MD; Elliot Fagelman, MD; Mary Hardy, MD; David Heber, MD, PhD, FACP, FACN; John Trimmer Hicks, MD, FACP, FACR; Hannah Kim, MD; Franklin C. Lowe, MD, MPH; Richard D. O'Connor, MD; Barry S. Oken, M.D; Lynn Shinto, ND; and Keith Wesnes, PhD.

Poor clinical trial designs result in failed studies wasting research funds and limiting the advancement of cures for disorders. Clinical Trial Design Challenges in Mood Disorders outlines classic problems researchers face in designing clinical trials and discusses how best to address them for the most definitive and generalizable results. Traditional trial designs are included as well as novel analytic techniques. The book examines information on high placebo response, the generalizability of studies conducted in the developing world, the duration of maintenance studies, and the application of findings into clinical practice. With representation from contributors throughout the world and from academia, industry, regulatory agencies, and advocacy groups, this book will contribute toward improved clinical trial design and valid, precise, and reliable answers about what works better and faster for patients.

A great deal of interest has been generated recently in the isolation, characterization, and biological activity of phytochemicals. Phytochemicals have the potential to enhance pharmaceuticals and drug discovery. As such, there is an urgent need for current research in the global scope of phytochemicals including the chemical and physical characteristics, analytical procedures, biological activity, safety, and industrial applications. The Handbook of Research on Advanced Phytochemicals and Plant-Based Drug Discovery examines the applications of bioactive molecules from a health perspective, examining the pharmacological aspects of medicinal plants, the phytochemical and biological activities of different natural products, and ethnobotany and medicinal properties. Moreover, it presents a novel dietary approach for human disease management. Covering topics such as computer-aided drug design, government regulation, and medicinal plant taxonomy, this major reference work is beneficial to pharmacists, medical practitioners, phytologists, hospital administrators, government officials, faculty and students of higher education, librarians, researchers, and academicians.

Proteins are exposed to various interfacial stresses during drug product development. They are subjected to air-liquid, liquid-solid, and, sometimes, liquid-liquid interfaces throughout the development cycle-from manufacturing of drug substances to storage and drug delivery. Unlike small molecule drugs, proteins are typically unstable at interfaces where, on adsorption, they often denature and form aggregates, resulting in loss of efficacy and potential immunogenicity. This book covers both the fundamental aspects of proteins at interfaces and the quantification of interfacial behaviors of proteins. Importantly, this book introduces the industrial aspects of protein instabilities at interfaces, including the processes that introduce new interfaces, evaluation of interfacial instabilities, and mitigation strategies. The audience that this book targets encompasses scientists in the pharmaceutical and biotech industry, as well as faculty and students from academia in the surface science, pharmaceutical, and medicinal chemistry areas.

"Lead Compounds from Medicinal Plants for the Treatment of Neurodegenerative Diseases" is the second volume in the series, "Pharmaceutical Leads from Medicinal Plants." This book includes key pharmacological and chemical evidence to support the selection of promising pre-clinical candidates for the treatment of neurodegenerative diseases.

This important addition to the natural product and drug discovery literature contains the history, synonyms, medicinal uses, phytopharmacology, pre-clinical potential, and rationale for each plant selected. By providing critical evaluation of pharmacological data, mechanisms of action, and structural requirements for the development of future neuroprotective agents, this comprehensive reference is a beneficial resource for industry and academic scientists whose research focuses on neurodegenerative drug discovery and development.
Incorporates compelling biological activity data and preclinical structure-activity relationships to help you choose promising lead molecules for further research Includes primary source references to the most recent natural product discoveries in the field of neuroprotection in order to promote new drug discovery in this areaContains detailed discussions of important neurodegenerative diseases, including Alzheimer's disease and Parkinson's diseaseEach plant section includes a critical evaluation of pharmacological, chemical, and toxicological evidence to support the use of the compound in drug discovery research in neurodegeneration